CYP19A1 and breast carcinoma: For instance, everolimus, an mTORC1 inhibitor developed for oral administration has shown to induce cell cycle arrest via autophagy-mediated degradation of cyclin D1 in breast cancer cells [138], while the same drug promotes autophagy in aromatase inhibitor-resistant breast cancer cells contributing to treatment resistance [139].